Introduction 30
Developments in newborn screening technologies, with Tthe expansion of newborn 31 bloodspot screening programmes (NBS), has have brought a substantial increase in the early 32 detection of rare inherited disorders (1) . In the USA, the NBS routinely tests for over thirty 33 conditions (2), and a similar expansion has occurred in other countries including the 34 Netherlands, Denmark and Germany (3) . In the United Kingdom (UK), more modest 35 expansions have resulted in the inclusion of six inherited metabolic conditions (Box 1) (4). 36
38
Screening and early detection of rare conditions enable treatment to be initiated before 39 significant morbidity has occurred, and can result in substantially improved health outcomes 40 and reduced likelihood of mortality (5). For example, the benefits of early detection and 41 active management for phenylketonuria are well established (6), and more recent evidence 42 indicates the benefits for medium chain Acyl-CoA dehydrogenase deficiency (MCADD) (7-43 11). The responsibility for managing these conditions, however, rests primarily with parents. 44
The associated family burden may be substantial (12), although there is some evidence that 45 this can be mediated by adequate support (13, 14) . 46
When a child is diagnosed with a recessive genetic condition, parents need to decide whether 47 or not to have subsequent children. Their reproductive choices are made within a highly 48 complex and changing healthcare, social, and technological contexts. Their decisions are 49 informed by various factors, such as the severity of the condition, and its impact on the child 50 they related to reproductive decision-making by couples who had a child with a recessive 105 genetic condition and were considering having more children. We excluded papers relating to 106 couples who did not have an affected child, or papers focusing on: (i) women with a genetic 107 condition; (ii) the uptake of genetic technologies without exploring the decision-making 108 process; or (iii) attitudes towards parental screening or (hypothetical) non-invasive prenatal 109 diagnosis. Included conditions of interest were those shown in bold in Box 1. We excluded 110 studies relating to autosomal dominant conditions (e.g. Huntingdon's), or other non-genetic 111 conditions (e.g. hypothyroidism). 112
We only included studies set in countries whose reproductive health services included well-113 developed early detection technologies, i.e. Europe, USA, Canada, Australia, and New 114
Zealand. We included papers that reported any original empirical study, but the reference lists 115 of retrieved reviews were consulted. 116
Data extraction and synthesis 117
We developed a data extraction form for We chartedcharting the key study characteristics of 118 the included studies and findings of relevance to our review, which were further thematically 119 analysed according to our review questions. 120
Results

121
Characteristics of included studies 122
From 311 unique records from the original database searches, plus two further records from 123 the search update, seven records were included in this review (see Figure 1) . 124
All were peer-reviewed journal articles apart from one conference abstract (22). The main 125 characteristics of the included studies are provided in Table 1 . 126
Four studies related to reproductive decision-making for parents of children with Cystic 127 Atrophy (SMA) (27), and rare metabolic disorders (28). In most of the studies the participants 129 were recruited from populations using, or known to, health services (22-26,28); one study 130 recruited predominantly via an advocacy group for the condition (SMA) (27). Four studies 131 used quantitative (23,24,26,28), and three qualitative research methods (22, 25, 27 In most studies, parental perceptions of coping with their affected child were key to decisions 152 about having any further children, and decisions about the use of reproductive technologies to 153 avoid having further affected children. Decisions were based on factors centred both on the 154 child, and on the parent and their wider family and social network, which. They included 155 perceptions around their current and future situation, which shifted over time as the parents 156 adapted to caring for their affected child.. 157
Factors centred on the child included the perceived severity (or otherwise) of the condition 158 (23,26), concerns about the child's current health (23), worry about the child's future and their 159 future health (23,28), the (poor) quality of life of the child and the family (23), the potential 160 impact of another affected child on the existing child and family life, including concern for 161 increased infection risk (25), and having experienced suffering and death of previous 162 children(27). In one study, some parents considered their existing child as a role model or 163 support system for a hypothetical future child having the same condition (22), and in another7 study (23) one mother believed that termination of an affected pregnancy would devalue the 165 life of their existing child with CF. 166
Factors centred on the parents included parental stress (28), the impact of caring for the child 167 on the parents' daily activities (26), the perceived difficulty of meeting the child's care needs 168 (28), the size of the parents' social support network (28), and the physical strain of caring for 169 a child with a condition involving a physical disability (27). In one study, the parents' 170 experience caring for their affected child gave them confidence in their abilities to look after 171 another child with the same condition (25); indeed, one father was quoted as saying they had 172 considered adopting another child with CF because of their experiences (25). 173
Some parents did plan future pregnancies but were prepared to take the risk of having a 174 further affected child, trusting to chance. In one study (23), some parents believed that the 175 odds were more likely to be in favour of having a healthy child in the next pregnancy. One 176 study found that some parents appeared not to make active reproductive choices, but rather 177 were 'overtaken by events' (25) p.409, which the authors described as a 'decision not to 178 decide'. Conversely, in another study (26) some parents of children with CF had decided not 179 to have more children as this was 'easier to decide', obviating potential engagement with 180 reproductive technologies. 181
Moral issues were of lesser importance in decision-making: lack of religious conviction was 182 found to correlate with intention to use PND and consideration of termination (26), and 2/16 183 mothers cited 'religious reasons' for not terminating a hypothetical affected pregnancy in one 184 study (23). One study found that for some parents the decision not to have any further 185 children was driven by a desire not to have any more affected children and unwillingness to 186 terminate an affected pregnancy (24). 187
The studies highlight much ambivalence around the use of PND to make decisions about 188 continuation of pregnancy. Three studies (23,26,28) explored parents' decision making and 189 reasoning in relation to hypothetical future pregnancies. In one study (26) Reproductive decisions may change as the situation of caring for a child with a rare genetic 200 condition unfolds. This has been explored only with respect to parents of children with CF. In 201 one study, participants describing their evolving response to having a child with CF (25) 202 reported that One of the studies invited participants to describe their evolving response to 203 having a child with CF (25). Participants reported that after the initial shock of diagnosis, 204 they took some time to adapt and learn how to manage the condition, but once they had 205 adapted, they felt able to cope and could consider having another child. 206
As decisions can change over time, hypothetical decisions may not necessarily translate to 207 actual behaviour. Only one study followed up participants over time to explore this how 208 hypothetical decisions translated to actual behaviour (23). They found that 16 of the 27 209 mothers of young children with CF who had at baseline reported not wanting any more 210 children, had changed their mind at a five-year follow-up. Again, coping was cited as a main 211 reason for this, along with the child's good health and being more comfortable with the 212 diagnosis. Conversely, four of the six mothers who originally wanted more children had 213 changed their mind due to concerns over the child's health. Overall, the study found that in 214 67% of mothers, the hypothetically reported behaviour regarding the use of PND was the 215 same as the actual behaviour, but 'mothers not uncommonly changed their minds, and in both 216 directions' (23) (pe654). 217
What is the involvement of healthcare services in supporting and facilitating these decisions? 218
Four studies (23-25, 28) considered the role of healthcare services and all confined their 219 attention to genetic counselling services and their availability, uptake and acceptability. Some 220 of the studies reported that some or all the participants had received genetic counselling, 221 mostly by specialist genetic counselling services (23-25); in the study of reproductive 222 decisions of parents of children with metabolic disorders (28), the author provided a 223 breakdown of professional groups which provided genetic counselling, and less than 4% of 224 genetic counselling was provided by a specialist genetic counsellor either within or outside 225 the metabolic centre. One study (23) reported that 72% of mothers had rated consultations9 with genetic counsellors as 'extremely useful' or 'very useful'. Other than reporting the 227 availability and uptake of genetic counselling services, however, the studies did not explore 228 the role of these or other services in supporting and facilitating reproductive decisions. 229
Discussion 230
We found a dearth of recent studies exploring reproductive decision-making of parents of 231 children with recessive genetic conditions, as previously highlighted (29); the collective 232 scope of the studies was narrow. Only a small number of conditions were considered, with 233 the majority focusing on CF, whose findings will have limited applicability to other 234
conditions. Most studies focused on attitudes towards, and uptake of, PND and termination. 235
None of the studies considered the wider range of reproductive choices facing all parents 236 (including those of children with conditions for whom PND and termination is not available 237 or where good health outcomes make these options less justifiable), and the extent to which 238 those choices are facilitated. With regard to familial relationships, only one of our included 239 studies (25) explored the role of both mothers and fathers in couples' reproductive decision-240 making; for most of the others, mothers were the focus. More generally, this literature base 241 failed to recognise that reproductive decisions take place in a wider social arena that extends 242 beyond the confines of PND (30). , and outside the confines of consideration of, and 243 engagement with, PND. 244
The reviewed literature did reveal a number of factors which seem to affect reproductive 245 decisions for this particular population and their relative importance. Many of those revolved 246 around parental perceptions of coping, now and in the future, with some parents using 247 scenario-based thinking as a decision-making strategy (25). Moral and religious 248 considerations seemed to be less significant which is consistent with findings from Atkin et al. 249
(301). 250
In presenting factors which may be important in reproductive decision-making, it is important 251 to recognise the complex interplay between them (25), and the ways in which parents manage 252 the complexity of decisions related to use of reproductive technologies. In some cases, this is 253 done using simplifying heuristics (25). Some who find reproductive decisions too 254 overwhelming choose not to choose, leaving future children to chance, rejecting PND and 255 therefore any subsequent, potentially stressful decisions (321). Others elect to eliminate the 256 possibility of future pregnancies altogether, as Kelly (29) Our review has benefited from rigorous database searches and study selection processes. The 286 grey literature searches, however, were not exhaustive., therefore some potentially relevant 287 materials may have been missed. It could be argued that oOne limitation was a decision not 288 to quality assess the included studies. However the role of quality assessment in scoping 289 reviews has been debated (36,37), and in our review we were not synthesising the evidence 290 on the basis of its strength and quality, but rather identifying emergent themes and identifying 291 gaps where research is lacking (387). 292
293
Conclusion 294
We found an overall paucity of research evidence on reproductive decision-making and the 295 role of reproductive health services. The evidence base was confined to a limited number of 296 conditions (predominantly CF). Although the studies were largely concerned with decisions 297 about the use of reproductive technologies, these decisions were secondary to fundamental 298 decisions about whether to have a further child. These decisions, which changed over time, 299 centred on the reality of caring for the affected child and its implications on the family unit. 300
There is a need to better understand what support parents need in their decision-making, how 301 and when best to provide it, and by whom. Mothers' voices dominated the current literature, 302 therefore subsequent research should focus more on the whole family unit. 303 (MH "Huntington Disease") 9,032 S12 S9 OR S10 OR S11 34,882 S13 S8 AND S12 110 S14 TI ( PKU OR phenylketonuria OR hyperphenylalaninemia OR "PAH deficiency" OR "phenylalanine hydroxylase deficiency" OR H-PHE ) OR AB ( PKU OR phenylketonuria OR hyperphenylalaninemia OR "PAH deficiency" OR "phenylalanine hydroxylase deficiency" OR H-PHE ) 6,379 S15 (MH "Phenylketonuria+") 518 S16 (MH "Phenylketonurias+") 6,102 S17 S14 OR S15 OR S16 8,193 S18 S8 AND S17 40 S19 TI "congenital hypothyroidism" OR AB "congenital hypothyroidism" S30 TI ( GA-1 OR GA1 OR GA-2 OR GA2 OR "glutaric acidemia" OR "glutaric aciduria" OR (glutaryl n4 deficiency) OR (glutarate n4 defect) OR "dicarboxcylic aminoaciduria" ) OR AB ( GA-1 OR GA1 OR GA-2 OR GA2 OR "glutaric acidemia" OR "glutaric aciduria" OR (glutaryl n4 deficiency) OR (glutarate n4 defect) OR "dicarboxcylic aminoaciduria" ) . The table only includes population and sample size data pertinent to the parents of affected children. SCD = Sickle Cell Disease; CF = Cystic Fibrosis; SMA = Spinal Muscular Atrophy; PND = pre-
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